General | ||
BD | Batten disease | |
BDFA | Batten Disease Family Association | |
BDSRA | Batten disease support and research Association | |
CNS | Clinical Nurse specialist | |
EMA | European Medicine Agency | |
EU | European Union | |
FDA | Federal Drug Administration | |
LSD | Lysosomal Storage Disease | |
MHRA | Medicines & Healthcare products Regulatory Agency | |
NCL | Neuronal Ceroid Lipofuscinoses | |
NHS | National Health Service | |
NICE | National Institute for Health and Care excellence | |
PO | Patient Organisation | |
HTA | Human Tissue Authority (UK) | |
Science | ||
PPT1 | palmitoyl-protein thioesterase 1 | |
TPP1 | tripeptidyl peptidase 1 | |
Medical | ||
CNS | Central nervous system | |
EHCP | Education, health and care plans | |
ERT | Enzyme replacement Therapy | |
GT | Gene Therapy | |
HST |
|
|
ICU | Intensive Care Unit | |
ICV | intro cerebroventricular | |
INCL | Infantile Batten disease | |
IVF |
|
|
JNCL | Juvenile Batten Disease | |
LINCL | Late Infantile Batten disease | |
PGD | pre-implantation genetic diagnosis | |
SEN | Special educational needs | |
SRT | Substrate Reduction Therapy | |
VI | Visual Impairment | |
vLINCL | Variant late infantile Batten disease |